Patents by Inventor Mark B. Zimering

Mark B. Zimering has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods of inhibiting the binding of plasma IGG autoantibodies to serotonin 2A receptor
    Patent number: 12122853
    Abstract: Disclosed herein, are decoy peptides or polypeptides capable of inhibiting binding of 5-HT2A autoantibodies to a second extracellular loop region of the 5-HT2A receptor, and a pharmaceutical composition containing the decoy peptides or polypeptides and methods of use.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: October 22, 2024
    Assignee: The United States Government As Represented By The Department of Veterans Affairs
    Inventor: Mark B. Zimering
  • COMPOSITIONS AND METHODS OF INHIBITING THE BINDING OF PLASMA IGG AUTOANTIBODIES TO SEROTONIN 2A RECEPTOR
    Publication number: 20240002467
    Abstract: Disclosed herein, are decoy peptides or polypeptides capable of inhibiting binding of 5-HT2A autoantibodies to a second extracellular loop region of the 5-HT2A receptor, and a pharmaceutical composition containing the decoy peptides or polypeptides and methods of use.
    Type: Application
    Filed: November 22, 2021
    Publication date: January 4, 2024
    Inventor: Mark B. Zimering
  • COMPOSITIONS AND METHODS OF INHIBITING THE BINDING OF PLASMA IGG AUTOANTIBODIES TO SEROTONIN 2A RECEPTOR
    Publication number: 20220204564
    Abstract: Disclosed herein, are decoy peptides or polypeptides capable of inhibiting binding of 5-HT2A autoantibodies to a second extracellular loop region of the 5-HT2A receptor, and a pharmaceutical composition containing the decoy peptides or polypeptides and methods of use.
    Type: Application
    Filed: March 4, 2022
    Publication date: June 30, 2022
    Inventor: MARK B. ZIMERING
  • Compositions and methods of inhibiting the binding of plasma IgG autoantibodies to serotonin 2A receptor
    Patent number: 11306122
    Abstract: Disclosed herein, are decoy peptides or polypeptides capable of inhibiting binding of 5-HT2A autoantibodies to a second extracellular loop region of the 5-HT2A receptor, and a pharmaceutical composition containing the decoy peptides or polypeptides and methods of use.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: April 19, 2022
    Assignee: The United States Government As Represented By The Department of Veterans Affairs
    Inventor: Mark B. Zimering
  • COMPOSITIONS AND METHODS OF INHIBITING THE BINDING OF PLASMA IGG AUTOANTIBODIES TO SEROTONIN 2A RECEPTOR
    Publication number: 20200392185
    Abstract: Disclosed herein, are decoy peptides or polypeptides capable of inhibiting binding of 5-HT2A autoantibodies to a second extracellular loop region of the 5-HT2A receptor, and a pharmaceutical composition containing the decoy peptides or polypeptides and methods of use.
    Type: Application
    Filed: June 9, 2020
    Publication date: December 17, 2020
    Inventor: MARK B. ZIMERING
  • NOVEL METHOD FOR PREDICTION OF CARDIOVASCULAR DISEASE RISK IN TYPE 2 DIABETES
    Publication number: 20110236386
    Abstract: The invention provides a method for diagnosing an increased risk of cardiovascular disease (CVD, including coronary heart disease (CHD)) in patients with type 2 diabetes comprising detecting basic fibroblast growth factor (bFGF) in a sample from the patient, an increased level of bFGF being indicative of increased risk of CHD, thereby diagnosing an increased risk of CHD in diabetic patients.
    Type: Application
    Filed: March 4, 2011
    Publication date: September 29, 2011
    Inventor: Mark B. Zimering
  • Method for identifying diabetic patients at increased risk for pathological complications
    Patent number: 7972798
    Abstract: The present invention provides methods for detecting and measuring, in a sample from a subject, the plasma levels of endothelial cell antibodies to diagnose an increased risk of pathological complications, such as visual impairment, associated with diabetes.
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: July 5, 2011
    Assignee: The United States of America as represented by the Department of Veterans Affairs
    Inventors: Mark B. Zimering, Zui Pan, Janet Alder, Smita Thakker-Varia
  • Novel method for identifying diabetic patients at increased risk for pathological complications
    Publication number: 20090208511
    Abstract: The present invention provides methods for detecting and measuring, in a sample from a subject, the plasma levels of endothelial cell antibodies to diagnose an increased risk of pathological complications, such as visual impairment, associated with diabetes.
    Type: Application
    Filed: December 4, 2008
    Publication date: August 20, 2009
    Inventors: Mark B. Zimering, Zui Pan, Janet Alder, Smita Thakker-Varia